Symbiomix Therapeutics Private
Symbiomix is a late-stage, privately-held biopharmaceutical company developing innovative medicines for serious womenвАЩs health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the worldвАЩs leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences, and HBM Partners. The CompanyвАЩs lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next-generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.
%20.jpg)
Estimated Revenue:
$10M to $50M
Headquarters:
Newark, New Jersey, United States
Employee Number:
11-50
Investment Stage:
N/A
Last Funding Date:
2018-01-01
Investors Number:
5
Funding Status:
M&A
Total Funding:
$47 000 000
Industry:
PharmTech
Investor Type:
Company
Number Of Exists:
Venture - Series Unknown
Technology:
Cancer
Last Funding Type:
Venture - Series Unknown
Founded Date:
2012